Equillium Inc
EQ
NASDAQ
Biotechnology
$2.36
USD
+0.35 (+17.41%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $127.40M
Volume 536.9K
Revenue
$0
TTM
-100.0%
YoY
Gross Margin
—
TTM
— YoY
Net Income
$-19.05M
TTM
-36.2%
YoY
Operating Cash Flow
$-18.88M
TTM
-2.6%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | -100.0% | -100.0% | -100.0% | -100.0% | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 2.9 | 2.1 | 3.3 | 2.4 | 2.6 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 8.9 | 6.2 | 4.6 | 4.0 | 5.6 |
Operating Income | -8.9 | -6.2 | -4.6 | -4.0 | -5.6 |
EBITDA | -8.8 | -6.2 | -4.5 | -3.9 | -5.6 |
Other Income / Expense | 0.0 | 0.4 | 0.1 | -0.1 | -0.0 |
Total Other Income / Expense | 0.2 | 0.5 | 0.3 | 0.2 | 0.3 |
Income Before Income Taxes | -8.7 | -5.7 | -4.2 | -3.8 | -5.3 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -8.7 | -5.7 | -4.2 | -3.8 | -5.3 |
Consolidated Net Income / Loss | -8.7 | -5.7 | -4.2 | -3.8 | -5.3 |
Net Income Attributable to Common Shareholders | -8.7 | -5.7 | -4.2 | -3.8 | -5.3 |
Basic EPS | -$0.24 | -$0.16 | -$0.06 | -$0.04 | -$0.06 |
Diluted EPS | -$0.24 | -$0.16 | -$0.06 | -$0.04 | -$0.06 |
Basic Shares Outstanding | 35.6M | 35.7M | 65.3M | 92.6M | 96.3M |
Diluted Shares Outstanding | 35.6M | 35.7M | 65.3M | 92.6M | 96.3M |